SIRPα blockade therapy inhibited SIRPα/CD47 axis-mediated PI3K/AKT signaling to suppress migration, PD-L1 expression of myeloid cells in vitro and HCC progression. This evidence concerns the gene CD274 and hepatocellular carcinoma.